semaglutide
PulseAugur coverage of semaglutide — every cluster mentioning semaglutide across labs, papers, and developer communities, ranked by signal.
- 2026-05-26 research_milestone New research indicates semaglutide may alleviate osteoarthritis-related inflammation and tissue damage, independent of weight loss. source
7 day(s) with sentiment data
-
GLP-1 drugs show promise for hormonal disorder PMOS
GLP-1 drugs, commonly used for weight loss and diabetes, are showing significant promise in treating polyendocrine metabolic ovarian syndrome (PMOS), a hormonal disorder affecting women. Early research and patient testi…
-
AI could help combat global fatty liver disease epidemic
Artificial intelligence may offer a solution to the growing global epidemic of fatty liver disease, which affects approximately 30 percent of adults worldwide and can lead to liver failure, cardiovascular disease, and c…
-
Tech Giants Face Lawsuits Over Social Media Addiction; GLP-1 Drugs Show Brain Health Promise
A recent court ruling allows thousands of lawsuits alleging social media addiction to proceed against tech giants like Meta. Separately, researchers are exploring the potential of GLP-1 drugs, such as Ozempic, to treat …
-
GLP-1 drugs show surprising benefits beyond weight loss
GLP-1 medications, commonly known for weight loss and type 2 diabetes treatment, are demonstrating a range of surprising health benefits beyond their initial applications. Recent trials indicate these drugs can protect …
-
GLP-1 drugs like Ozempic may cause unlisted side effects, study finds
New research indicates that GLP-1 medications like Ozempic and Wegovy may have side effects not listed on their labels. A study analyzing Reddit posts found that nearly half of semaglutide and tirzepatide users reported…
-
Medicare launches GLP-1 bridge program for weight loss drugs
The Medicare Bridge program, initiated by the Trump administration, offers eligible seniors and disabled individuals access to certain GLP-1 weight loss medications for a flat $50 monthly co-payment. This demonstration …
-
FDA reviews popular peptides amid safety and efficacy concerns · 2 sources tracked
The U.S. Food and Drug Administration (FDA) is set to review seven peptides for potential approval for compounding by pharmacies. These peptides, including BPC-157, TB-500, and Semax, are popular in longevity and wellne…
-
Medicare launches $50/month GLP-1 weight loss drug program
The Trump administration has launched a temporary Medicare Bridge program to provide some beneficiaries with access to popular weight loss medications like tirzepatide and semaglutide for a flat $50 monthly co-payment. …
-
GLP-1 weight-loss drugs drive major climate impact by cutting food demand
The widespread adoption of GLP-1 medications for weight loss is having a significant, albeit unintended, impact on the climate by reducing demand for carbon-intensive foods. As more Americans use drugs like semaglutide …
-
Novo Nordisk CEO eyes longevity and aesthetics beyond weight loss drugs
Novo Nordisk's CEO, Mike Doustdar, is exploring new therapeutic areas beyond weight loss and diabetes, including longevity and aesthetic medicine. The company is investigating semaglutide's potential to protect vital or…
-
GLP-1 drugs show anti-inflammatory benefits beyond weight loss
GLP-1 medications like Ozempic and Wegovy, known for weight loss, are showing promise in treating inflammation and tissue damage, particularly in osteoarthritis. A study in Cell Metabolism found semaglutide reduced infl…
-
US considers AI oversight, China drug firm seeks global partners
Guoyao Taiji's investigational drug semaglutide was showcased at the Canton Fair, initiating global investment outreach. The company has established API and formulation production facilities compliant with Chinese and U…